Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Climb BioCLYM -0.40%22 3-Year EBITDA Growth Rate is 16.50% as of Jun. 2026, which is 1169% above its 10-year median of 1.30. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,130 Biotechnology companies, Climb Bio ranks better than 51.86% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 12.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Climb Bio was 39.90% per year. The lowest was -35.70% per year. And the median was 1.30% per year.
Climb Bio (NAS:CLYM) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Climb Bio 3-Year EBITDA Growth Rate Related Terms
CLYM vs DSGN, MNPR, ACRS: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Climb Bio's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Climb Bio 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Climb Bio's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Climb Bio's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 16.50% mean?
Climb Bio (CLYM) has a 3-Year EBITDA Growth Rate of 16.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Climb Bio and its competitors. This is 1169% above median its historical median of 1.30. According to the industry distribution chart, Climb Bio ranks #544 out of 1130 companies in the Biotechnology industry, placing it in the top 48.1%.
Is Climb Bio's 3-Year EBITDA Growth Rate too high?
Climb Bio's current 3-Year EBITDA Growth Rate of 16.50% is 1169% above median its 10-year median of 1.30. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Climb Bio's value of 16.50% is 11.1% above this industry median. Based on the distribution chart, Climb Bio ranks #544 out of 1130 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's 3-Year EBITDA Growth Rate compare to DSGN and MNPR?
According to the Biotechnology industry distribution chart, Climb Bio ranks #544 out of 1130 companies for 3-Year EBITDA Growth Rate. This puts Climb Bio in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Climb Bio's value of 16.50% is 11.1% above this benchmark. While the company's 10-year median is 1.30 vs. the industry median of 14.85, Climb Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Climb Bio's current 3-Year EBITDA Growth Rate of 16.50% is 11.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Climb Bio and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Climb Bio's current 3-Year EBITDA Growth Rate is 16.50%, which is 1169% above median its own 10-year median of 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current 3-Year EBITDA Growth Rate of 16.50%. The current 3-Year EBITDA Growth Rate is 16.50%, which is 1169% above median its 10-year median of 1.30 and 11.1% above the Biotechnology industry median of 14.85. Climb Bio's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Climb Bio (CLYM), the current 3-Year EBITDA Growth Rate is 16.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score
Get the complete analysis for CLYM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYM has been successfully added to your 
